BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34846682)

  • 1. Speed of response to dopaminergic agents in prolactinomas.
    Hage C; Salvatori R
    Endocrine; 2022 Mar; 75(3):883-888. PubMed ID: 34846682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
    Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
    Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant prolactinomas, a detailed analysis of 196 adult cases.
    Lisa B; Arno V; Christophe B; Heyning Paul V; Carlien H
    Pituitary; 2023 Oct; 26(5):529-537. PubMed ID: 37544978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactinomas.
    Wildemberg LE; Fialho C; Gadelha MR
    Presse Med; 2021 Dec; 50(4):104080. PubMed ID: 34687915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prolactin per Unit Tumor Volume Ratio Accurately Distinguishes Prolactinomas From Secondary Hyperprolactinemia due to Stalk Effect.
    Faje A; Jones P; Swearingen B; Tritos NA
    Endocr Pract; 2022 Jun; 28(6):572-577. PubMed ID: 35339688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprolactinemia after menopause: Diagnosis and management.
    Auriemma RS; Pirchio R; Pivonello R; Colao A
    Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.
    Cho A; Vila G; Marik W; Klotz S; Wolfsberger S; Micko A
    Front Endocrinol (Lausanne); 2022; 13():901385. PubMed ID: 36147567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperprolactinemia in the postmenopause: versions and contraversions].
    Leshchenko OY
    Ter Arkh; 2021 Oct; 93(10):1234-1239. PubMed ID: 36286827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Dopamine Agonist Therapy Withdrawal in Children with Prolactinomas.
    Almutlaq N; Eugster EA; Nabhan Z; Donegan D
    Horm Res Paediatr; 2022; 95(3):291-295. PubMed ID: 35609555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of prolactin and the role of dopamine agonists: A review.
    Kirsch P; Kunadia J; Shah S; Agrawal N
    Front Endocrinol (Lausanne); 2022; 13():1002320. PubMed ID: 36246929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GIANT PROLACTINOMA. A CASE REPORT.
    Šulavíková Z; Krásnik V
    Cesk Slov Oftalmol; 2023; 79(3):143-148. PubMed ID: 37344216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review.
    Paracha A; Durrani U; Vasireddy S; Abid A; Waheed F; Thomure M
    J Psychiatr Pract; 2024 May; 30(3):200-211. PubMed ID: 38819244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Prolactin Level to Tumor Size Ratio as a Potential Parameter for Preoperative Differentiation of Prolactinomas from Hyperprolactinemia-Causing Non-functional Pituitary Adenomas.
    Kim JH; Hur KY; Hong SD; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
    World Neurosurg; 2022 Mar; 159():e488-e496. PubMed ID: 34958988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
    Heneghan LJ; Tsang A; Dimino C; Khandji AG; Panigrahi SK; Page-Wilson G
    J Clin Endocrinol Metab; 2024 Jan; 109(2):e667-e674. PubMed ID: 37715962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men.
    Rudman Y; Duskin-Bitan H; Richter I; Tsvetov G; Masri-Iraqi H; Akirov A; Shimon I
    Andrology; 2023 Oct; 11(7):1398-1407. PubMed ID: 36897756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive Giant Prolactinoma.
    Alkhaibary A; Alharbi A; Khairy S
    World Neurosurg; 2024 Jan; 181():21-22. PubMed ID: 37827431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.
    Wang L; Wang X; Gong F; Pan H; Zhu H
    Front Endocrinol (Lausanne); 2023; 14():1285477. PubMed ID: 38093965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
    Benetti-Pinto CL; Prestes Nácul A; Rosa-E-Silva ACJS; Maciel GAR; Dos Santos Nunes Nogueira V; Condé Lamparelli Elias P; Martins M; Kasuki L; Mendes Garmes H; Glezer A
    Arch Endocrinol Metab; 2024 Apr; 68():e230504. PubMed ID: 38578473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
    Petersenn S; Fleseriu M; Casanueva FF; Giustina A; Biermasz N; Biller BMK; Bronstein M; Chanson P; Fukuoka H; Gadelha M; Greenman Y; Gurnell M; Ho KKY; Honegger J; Ioachimescu AG; Kaiser UB; Karavitaki N; Katznelson L; Lodish M; Maiter D; Marcus HJ; McCormack A; Molitch M; Muir CA; Neggers S; Pereira AM; Pivonello R; Post K; Raverot G; Salvatori R; Samson SL; Shimon I; Spencer-Segal J; Vila G; Wass J; Melmed S
    Nat Rev Endocrinol; 2023 Dec; 19(12):722-740. PubMed ID: 37670148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
    Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
    J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.